KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Inventory (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Change in Inventory data on record, last reported at -$4.8 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 135.9% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached $27.6 million, up 31.72%, while the annual FY2025 figure was $27.6 million, 31.72% up from the prior year.
  • Change in Inventory reached -$4.8 million in Q4 2025 per PCRX's latest filing, down from $9.5 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $14.4 million in Q2 2025 and bottomed at -$7.6 million in Q1 2024.
  • Average Change in Inventory over 5 years is $2.9 million, with a median of $1.9 million recorded in 2021.
  • The widest YoY moves for Change in Inventory: up 11988.37% in 2022, down 567.17% in 2022.
  • A 5-year view of Change in Inventory shows it stood at $1.9 million in 2021, then tumbled by 138.54% to -$735000.0 in 2022, then soared by 1165.71% to $7.8 million in 2023, then surged by 71.29% to $13.4 million in 2024, then crashed by 135.9% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$4.8 million in Q4 2025, $9.5 million in Q3 2025, and $14.4 million in Q2 2025.